Stock DNA
Pharmaceuticals & Biotechnology
SEK 195 Million ()
NA (Loss Making)
NA
0.00%
-1.62
-827.60%
10.98
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-41 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-49.23%
0%
-49.23%
6 Months
-12.95%
0%
-12.95%
1 Year
-55.8%
0%
-55.8%
2 Years
-57.34%
0%
-57.34%
3 Years
-97.82%
0%
-97.82%
4 Years
-98.99%
0%
-98.99%
5 Years
-99.3%
0%
-99.3%
Immunovia AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.99%
EBIT Growth (5y)
3.42%
EBIT to Interest (avg)
-57.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.28
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
11.90
EV to EBIT
-1.89
EV to EBITDA
-2.11
EV to Capital Employed
-16.49
EV to Sales
182.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-827.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-19.70
-17.20
-14.53%
Interest
21.00
38.90
-46.02%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-41.10
-57.80
28.89%
Operating Profit Margin (Excl OI)
-222,488.90%
-129,877.70%
-9,261.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.00% vs -80.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 28.89% vs -1,964.52% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.90
1.60
-43.75%
Operating Profit (PBDIT) excl Other Income
-93.50
-153.40
39.05%
Interest
1.90
1.20
58.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-76.50
-309.40
75.27%
Operating Profit Margin (Excl OI)
-114,887.20%
-187,383.50%
7,249.63%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -43.75% vs 45.45% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 75.27% vs -84.06% in Dec 2023
About Immunovia AB 
Immunovia AB
Pharmaceuticals & Biotechnology
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Company Coordinates 
Company Details
Medicon Village, Scheelevagen 2 , LUND None : 223 81
Registrar Details






